RxDoctor Payments Data

Robert Tatum, PA

Physician Assistant · Louisville, KYNPI 1801841325

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $19,685 of the $29,211 with a category attached, or 67.4%. 6 manufacturers reported payments, led by Intercept Pharmaceuticals, Inc. at 53.2% of the total. 2025 is the largest year on record at $9,463, 7.1 times the $1,330 reported in 2021. Among physician assistant clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$29,211in general payments, 2019–2025

Across 77 payments — averaging $379.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intercept Pharmaceuticals, Inc.$16K
  • Madrigal Pharmaceuticals$9K
  • Ipsen Biopharmaceuticals, Inc$4K
  • Gilead$122
  • Novo Nordisk$101
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$30

What the payments were for

  • Consulting fees$2,4108%
  • Speaking & faculty fees$19,68567%
  • Travel & lodging$4,74516%
  • Food & beverage$2,3718%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,211 in reported general payments places this provider in the 95th percentile of 1,448 physician assistant providers in Kentucky.

See all physician assistant providers in Kentucky

Medicare billing

Part B allowed, 2024
$7,503
Medicare patients
66
Services billed
96

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin36$118,231
VemlidyTenofovir Alafenamide25$34,772
Ursodiol20$4,737
Mycophenolate Mofetil25$3,328
Lactulose40$1,836
Spironolactone31$193
Pantoprazole Sodium11$129
Carvedilol46$83
Prednisone11$64
Omeprazole15$52
Furosemide27$26

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$30$118,23136 claims
GileadVemlidy$122$34,77225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,448 physician assistant providers in Kentucky.

Other physician assistant in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →